Renal CancerNCT04213157
Laparoscopic Partial Nephrectomy for cT1 Tumors
An observational study of Renal Cancer and Renal Neoplasm, run by Samsun Liv Hospital at 2 sites in Turkey (Türkiye).
Trial summary
The aim of the study is to evaluate trifecta and pentafecta outcomes for laparoscopic partial nephrectomy (LNP) in patients with clinical T1N0M0 renal tumor. Read more about this study
- Who is it for?
- Ages 18 to 82 years
- Conditions the study is for
- Renal Cancer, Renal Neoplasm, Renal Cell Carcinoma
- How many people
- 292 participants
- Where
- 2 sitesTurkey (Türkiye)
- Study dates
- 15 Mar 2019to 10 Nov 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 82 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Two hundred ninety-two patients who have a follow-up at least 12 months were included in the study. Those were allocated into two groups according to radiological tumor size; 215 patients with tumor size ≤ 40 mm were included in group T1a and 77 patients with tumor size 41-70 mm were included in group T1b.
Who may be able to join
- Functioning contraleteral kidney
- Patients with complete data
- Patients with single renal tumor on the effected side
- Patients who approved the written consent form
Who cannot join
- The patients with bilateral renal tumors (n=8, 16 LPNs)
- solitary kidney (n=8)
- horseshoe kidney (n=4)
- pelvic ectopic kidney (n=2)
- graft kidney (n=2)
- those with multiple renal tumors in a single kidney (n=3) or with > 7 cm renal tumor (n=6)
- Patients who were operated on for colon cancer (n=4), prostate cancer (n=2), endometrial cancer (n=1) or adrenal mass (n=2) within the first year after LPN
Trial locations and contacts
2 sites in 1 country.
Turkey (Türkiye)2 sites
Liv hospital samsun
Samsun, 55020
Ondokuz Mayıs University
Samsun, 55030
About this study
Official title: Evaluation Trifecta and Pentafecta Outcomes of Patients Underwent Laparoscopic Partial Nephrectomy for cT1 Renal Tumor
The aim of the study is to evaluate trifecta and pentafecta outcomes for laparoscopic partial nephrectomy (LNP) in patients with clinical T1N0M0 renal tumor.
Read the detailed description
From November 2009 to August 2018 a total of 292 patients who underwent LPN by global ischemia were included in the study. The patients were allocated into two groups according to the tumor size; T1a (≤ 40 mm, n=215), T1b (41-70 mm, n=77). Demographics features, clinical tumor characteristics, intraoperative and postoperative outcomes were analyzed. A negative surgical margin, warm ischemia time (WIT) < 20 min and no postoperative complications (Clavien-Dindo ≥ grade 3) were accepted to achieve the trifecta outcomes. Pentafecta has defined as trifecta criteria plus >90% preservation of estimated glomerular filtration rate (eGFR) and no stage upgrade of chronic kidney disease 12 months after LPN. Univariable and multivariable analysis were used to identify factors predicting trifecta and pentafecta achievement.
- Conditions
- Renal Cancer, Renal Neoplasm, Renal Cell Carcinoma, Surgery, Surgery--Complications, Renal Functional Abnormality
- Keywords
- laparoscopic partial nephrectomy, Trifecta, Pentafecta, Outcomes
- Medical subject headings
- Kidney Neoplasms, Carcinoma, Renal Cell, Neoplasms, Urologic Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Operation time
time from onset to complete of surgery
Measured: at the end of the surgery
Blood loss
amount of bleeding during surgery (mL)
Measured: at the end of the surgery
warm ischemia time
The clamp time of the renal artery and vein which is required to complete tumor excision and renorrhaphy
Measured: at the and of the surgery
intraoperative complication
abnormal problmes that may be seen during surgery
Measured: at the end of the surgery
Postoperative complication
abnormal problmes that may be seen after surgery and require additional intervention, treatment or follow-up
Measured: up to 3 months
functional outcomes
serum creatinine level and estimated glomerular filtration rate
Measured: up to 1 year postoperatively
surigcal margin status
presence or absence of tumors at the surgical margin
Measured: up to 1 month postoperatively
Relative decrease in renal function
Comparison of preoperative and postoperative renal functions according to numerical and percentile values
Measured: up to 1 year postoperatively
CKD stage upgrading
evaluation of preoperative and postoperative renal functions according to chronic kidney disease stages
Measured: up to 1 year postoperatively
Oncological outomes
Presence or absence of local and/or distal tumor recurrence
Measured: up to the last clinical control (months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Dec 2019
- Study start15 Mar 2019
- Primary completion30 Aug 2019
- Study completion10 Nov 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Renal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 292 participants (actual)
Sponsor and investigators
- Lead sponsor
- Samsun Liv Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Ondokuz Mayıs University
- Responsible party
- Principal investigator, Mehmet Necmettin Mercimek, Samsun Liv Hospital
- Investigators
- Saban Sarıkaya, Professor, Study chair, Ondokuz Mayıs UniversityEnder Ozden, Professor, Study director, Ondokuz Mayıs University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04213157
- Sponsor's protocol ID
- OMU KAEK 2019/241
- Status last verified
- Dec 2019
- First submitted
- 25 Dec 2019
- Last updated
- 2 Jan 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: It is not yet known if there will be a plan to make IPD available.
Publications
Porpiglia F, Bertolo R, Amparore D, Fiori C. Margins, ischaemia and complications rate after laparoscopic partial nephrectomy: impact of learning curve and tumour anatomical characteristics. BJU Int. 2013 Dec;112(8):1125-32. doi: 10.1111/bju.12317. Epub 2013 Aug 13.
PubMed 23937616Minervini A, Siena G, Antonelli A, Bianchi G, Bocciardi AM, Cosciani Cunico S, Ficarra V, Fiori C, Fusco F, Mari A, Martorana G, Medica M, Mirone V, Morgia G, Porpiglia F, Rocco F, Rovereto B, Schiavina R, Simeone C, Terrone C, Volpe A, Carini M, Serni S; Members of the RECORd Project-LUNA Foundation. Open versus laparoscopic partial nephrectomy for clinical T1a renal masses: a matched-pair comparison of 280 patients with TRIFECTA outcomes (RECORd Project). World J Urol. 2014 Feb;32(1):257-63. doi: 10.1007/s00345-013-1155-7. Epub 2013 Sep 7.
PubMed 24013181Osaka K, Makiyama K, Nakaigawa N, Yao M. Predictors of trifecta outcomes in laparoscopic partial nephrectomy for clinical T1a renal masses. Int J Urol. 2015 Nov;22(11):1000-5. doi: 10.1111/iju.12893. Epub 2015 Aug 6.
PubMed 26251228Rais-Bahrami S, Romero FR, Lima GC, Kohanim S, Permpongkosol S, Trock BJ, Jarrett TW, Kavoussi LR. Elective laparoscopic partial nephrectomy in patients with tumors >4 cm. Urology. 2008 Sep;72(3):580-3. doi: 10.1016/j.urology.2008.05.027. Epub 2008 Jul 16.
PubMed 18632142Mercimek MN, Ozden E, Gulsen M, Yakupoglu YK, Bostanci Y, Sarikaya S. Which Is the Best Predictor to Achieve Trifecta in Patients Undergoing Elective Laparoscopic Partial Nephrectomy with Global Hilar Clamping? Comparative Analysis in Patients with Clinical T1a and T1b Renal Tumors. J Endourol. 2021 May;35(5):615-622. doi: 10.1089/end.2020.0758. Epub 2020 Nov 5.
PubMed 32967451
Study at a glance
From the registry record, last updated by the sponsor on 2 Jan 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation Trifecta and Pentafecta Outcomes of Patients Underwent Laparoscopic Partial Nephrectomy for cT1 Renal Tumor
- ClinicalTrials.gov ID
- NCT04213157
- Acronym / sponsor ID
- OMU KAEK 2019/241
- Conditions
- Renal Cancer, Renal Neoplasm, Renal Cell Carcinoma, Surgery, Surgery--Complications, Renal Functional Abnormality
- Keywords
- laparoscopic partial nephrectomy, Trifecta, Pentafecta, Outcomes
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 292 participants (actual)
- Lead sponsor
- Samsun Liv HospitalUniversity, hospital or other
- Collaborators
- Ondokuz Mayıs University
- Study start
- 15 Mar 2019 (actual)
- Primary completion
- 30 Aug 2019 (actual)
- Study completion
- 10 Nov 2019 (actual)
- First posted
- 30 Dec 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to evaluate trifecta and pentafecta outcomes for laparoscopic partial nephrectomy (LNP) in patients with clinical T1N0M0 renal tumor.
Detailed description
From November 2009 to August 2018 a total of 292 patients who underwent LPN by global ischemia were included in the study. The patients were allocated into two groups according to the tumor size; T1a (≤ 40 mm, n=215), T1b (41-70 mm, n=77). Demographics features, clinical tumor characteristics, intraoperative and postoperative outcomes were analyzed. A negative surgical margin, warm ischemia time (WIT) < 20 min and no postoperative complications (Clavien-Dindo ≥ grade 3) were accepted to achieve the trifecta outcomes. Pentafecta has defined as trifecta criteria plus >90% preservation of estimated glomerular filtration rate (eGFR) and no stage upgrade of chronic kidney disease 12 months after LPN. Univariable and multivariable analysis were used to identify factors predicting trifecta and pentafecta achievement.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 82 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Two hundred ninety-two patients who have a follow-up at least 12 months were included in the study. Those were allocated into two groups according to radiological tumor size; 215 patients with tumor size ≤ 40 mm were included in group T1a and 77 patients with tumor size 41-70 mm were included in group T1b.
Key inclusion criteria (4 listed)
- Functioning contraleteral kidney
- Patients with complete data
- Patients with single renal tumor on the effected side
- Patients who approved the written consent form
Key exclusion criteria (7 listed)
- The patients with bilateral renal tumors (n=8, 16 LPNs)
- solitary kidney (n=8)
- horseshoe kidney (n=4)
- pelvic ectopic kidney (n=2)
- graft kidney (n=2)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Operation time
Time frame: at the end of the surgery
time from onset to complete of surgery
Blood loss
Time frame: at the end of the surgery
amount of bleeding during surgery (mL)
warm ischemia time
Time frame: at the and of the surgery
The clamp time of the renal artery and vein which is required to complete tumor excision and renorrhaphy
intraoperative complication
Time frame: at the end of the surgery
abnormal problmes that may be seen during surgery
Postoperative complication
Time frame: up to 3 months
abnormal problmes that may be seen after surgery and require additional intervention, treatment or follow-up
functional outcomes
Time frame: up to 1 year postoperatively
serum creatinine level and estimated glomerular filtration rate
surigcal margin status
Time frame: up to 1 month postoperatively
presence or absence of tumors at the surgical margin
Relative decrease in renal function
Time frame: up to 1 year postoperatively
Comparison of preoperative and postoperative renal functions according to numerical and percentile values
CKD stage upgrading
Time frame: up to 1 year postoperatively
evaluation of preoperative and postoperative renal functions according to chronic kidney disease stages
Oncological outomes
Time frame: up to the last clinical control (months)
Presence or absence of local and/or distal tumor recurrence
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jan 2020.
- Results publication: PubMed 23937616Porpiglia F, Bertolo R, Amparore D, Fiori C. Margins, ischaemia and complications rate after laparoscopic partial nephrectomy: impact of learning curve and tumour anatomical characteristics. BJU Int. 2013 Dec;112(8):1125-32. doi: 10.1111/bju.12317. Epub 2013 Aug 13.
- Results publication: PubMed 24013181Minervini A, Siena G, Antonelli A, Bianchi G, Bocciardi AM, Cosciani Cunico S, Ficarra V, Fiori C, Fusco F, Mari A, Martorana G, Medica M, Mirone V, Morgia G, Porpiglia F, Rocco F, Rovereto B, Schiavina R, Simeone C, Terrone C, Volpe A, Carini M, Serni S; Members of the RECORd Project-LUNA Foundation. Open versus laparoscopic partial nephrectomy for clinical T1a renal masses: a matched-pair comparison of 280 patients with TRIFECTA outcomes (RECORd Project). World J Urol. 2014 Feb;32(1):257-63. doi: 10.1007/s00345-013-1155-7. Epub 2013 Sep 7.
- Results publication: PubMed 26251228Osaka K, Makiyama K, Nakaigawa N, Yao M. Predictors of trifecta outcomes in laparoscopic partial nephrectomy for clinical T1a renal masses. Int J Urol. 2015 Nov;22(11):1000-5. doi: 10.1111/iju.12893. Epub 2015 Aug 6.
- Results publication: PubMed 18632142Rais-Bahrami S, Romero FR, Lima GC, Kohanim S, Permpongkosol S, Trock BJ, Jarrett TW, Kavoussi LR. Elective laparoscopic partial nephrectomy in patients with tumors >4 cm. Urology. 2008 Sep;72(3):580-3. doi: 10.1016/j.urology.2008.05.027. Epub 2008 Jul 16.
- Derived from this study: PubMed 32967451Mercimek MN, Ozden E, Gulsen M, Yakupoglu YK, Bostanci Y, Sarikaya S. Which Is the Best Predictor to Achieve Trifecta in Patients Undergoing Elective Laparoscopic Partial Nephrectomy with Global Hilar Clamping? Comparative Analysis in Patients with Clinical T1a and T1b Renal Tumors. J Endourol. 2021 May;35(5):615-622. doi: 10.1089/end.2020.0758. Epub 2020 Nov 5.
- Individual participant dataSharing planned: Undecided. It is not yet known if there will be a plan to make IPD available.
Related trials for Renal Cancer
RecruitingPhase 3
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
RecruitingObservational study
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
Renal Tumor Histology, Cutaneous Leiomyoma
Active, not recruitingPhase 3
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Enrolling by invitation
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
Adenocarcinoma, Prostate Neoplasms
Not yet recruitingPhase 2
Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma
Locally Advanced Clear Cell Renal Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Saban Sarıkaya, Professor study chair
Ondokuz Mayıs University
Ender Ozden, Professor study director
Ondokuz Mayıs University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Renal Cancer and Renal Neoplasm, run by Samsun Liv Hospital at 2 sites in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Operation time (time frame: at the end of the surgery). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04213157, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jan 2020.